GlassScriptPhysician profile
Bryan G Furst
NPI 1992960405
$1,645.74
in general payments reported to CMS, 2019-2025
19 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.90 · 2023: $22.89 · 2024: $535 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $445.52 | 2024-2025 | |
| Amgen INC. | $174.96 | 2024-2025 | Evenity, Prolia, Prolia |
| Dexcom, INC. | $150.66 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $147.82 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $126.58 | 2024-2025 | Airsupra, Farxiga |
| Daiichi Sankyo INC. | $103.55 | 2024-2025 | Injectafer |
| Glaxosmithkline, LLC. | $82.58 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $64.22 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $60.72 | 2024-2025 | Jardiance, Mounjaro |
| Astellas Pharma US INC | $44.45 | 2025 | Veozah |
| Sumitomo Pharma America, INC. | $37.80 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.30 | 2025 | Xifaxan |
| Exact Sciences Corporation | $34.33 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Vertex Pharmaceuticals Incorporated | $27.29 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $26.67 | 2025 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $21.90 | 2020 | |
| Abbott Laboratories | $21.74 | 2024 | Proclaim |
| Aimmune Therapeutics, INC. | $20.02 | 2025 | Zenpep |
| Bayer Healthcare Pharmaceuticals INC. | $18.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Furst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.